PharmaShots

GSK & Spero Therapeutics Reports Early Conclusion of P-III (PIVOT-PO) Trial of Tebipenem HBr for Complicated Urinary Tract Infections (cUTIs)

Shots:GSK & Spero Therapeutics have reported early conclusion of P-III (PIVOT-PO) trial for efficacy of tebipenem HBr to treat cUTIs, incl. pyelonephritis following IDMC recommendation based on positive interim…

3 days ago

News

Alcon Reports the US FDA’s Approval of Tryptyr to Treat Dry Eye Disease

Shots:The US FDA has approved Tryptyr (0.003% acoltremon ophthalmic solution; AR-15512) to treat signs & symptoms of dry eye disease (DED); US launch expected in Q3’25Approval was backed…

3 days ago

News

The US FDA Grants Priority Review to Bayer’s Sevabertinib for HER2-mutant NSCLC

Shots:The US FDA has granted priority review to sevabertinib (BAY 2927088; reversible TKI) for the treatment of previously treated pts with advanced NSCLC harboring HER2 mutationsDesignation was based on…

3 days ago

News

SNAP Biosciences Licenses Monarch Therapeutics’ Technology to Advance Snap-Car NK Cell Therapy for Cancer Targets

Shots:SNAP Biosciences & Monarch Therapeutics have entered into a licensing agreement for Monarch’s small molecule adaptor tech to develop & commercialize SNAP's Snap-Car NK cell therapy platform in oncology…

3 days ago

News

Alvotech Expands its Partnership with Advanz Pharma to Commercialize Three Additional Biosimilars in the EU

Shots:Alvotech has entered into an agreement with Advanz Pharma to expand their commercial partnership to include 3 more biosimilar candidatesAs per the deal, Advanz will register & commercialize…

3 days ago

News

Rezolute Reports Enrollment Completion in P-III (sunRIZE) Trial of Ersodetug for Congenital Hyperinsulinism

Shots:Rezolute has completed pts enrollment in P-III (sunRIZE/RZ358-301) trial of ersodetug as an add-on treatment of hypoglycemia in congenital hyperinsulinism pts, with 62 pts enrolled, exceeding the target of 56; the…

3 days ago

INSIGHTS+

Disease of the Month – Atherosclerosis

Shots: Characterized by the thickening or hardening of arteries due to plaque buildup, atherosclerosis leads to complications like heart attack or stroke PharmaShots' Disease of the Month report aims to…

4 days ago

News

Merck KGaA to Present P-III (MANEUVER) Trial Data of Pimicotinib for Tenosynovial Giant Cell Tumor at ASCO 2025

Shots:Part 1 of P-III (MANEUVER) trial assessed pimicotinib (n=63) vs PBO (n=31) for 24wks. in 94 TGCT pts who required systemic therapy & had no prior anti-CSF-1/CSF-1R treatment; trial…

4 days ago

Video

LIFE SCIENCES | DAILY NEWS | MAY 28, 2025 | PHARMASHOTS

4 days ago

News

Biogen Joins Forces with City Therapeutics to Develop Novel RNAi Therapies

Shots:Biogen has collaborated with City Therapeutics to develop novel RNAi therapies, leveraging the former’s drug delivery tech & City’s RNAi engineering techAs per the deal, City will receive…

GSK & Spero Therapeutics Reports Early Conclusion of P-III (PIVOT-PO) Trial of Tebipenem HBr for Complicated Urinary Tract Infections (cUTIs)

Alcon Reports the US FDA’s Approval of Tryptyr to Treat Dry Eye Disease

The US FDA Grants Priority Review to Bayer’s Sevabertinib for HER2-mutant NSCLC

SNAP Biosciences Licenses Monarch Therapeutics’ Technology to Advance Snap-Car NK Cell Therapy for Cancer Targets

Alvotech Expands its Partnership with Advanz Pharma to Commercialize Three Additional Biosimilars in the EU

Rezolute Reports Enrollment Completion in P-III (sunRIZE) Trial of Ersodetug for Congenital Hyperinsulinism

Disease of the Month – Atherosclerosis

Merck KGaA to Present P-III (MANEUVER) Trial Data of Pimicotinib for Tenosynovial Giant Cell Tumor at ASCO 2025

LIFE SCIENCES | DAILY NEWS | MAY 28, 2025 | PHARMASHOTS

Biogen Joins Forces with City Therapeutics to Develop Novel RNAi Therapies

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter